Off-label prescribing for allergic diseases in children

Diana Silva1,2*, Ignacio Ansotegui3 and Mário Morais-Almeida2,4

Abstract

The majority of drugs prescribed have not been tested in children and safety and efficacy of children’s medicines are frequently supported by low quality of evidence. Therefore, a large percentage of prescriptions for children in the clinical daily practice are used off label. Despite the several recent legislation and regulatory efforts performed worldwide, they have not been successful in increasing availability of medicines adapted to children. Moreover, if we consider that 30% of the prescribed drugs for children are for the respiratory field and only 4% of new investigation projects for children research were proposed to access drugs for respiratory and allergy treatment, there is a clear imbalance of the children needs in this therapeutic area. This narrative review aimed to describe and discuss the off-label use of medicines in the treatment and control of respiratory and allergic diseases in children. It was recognized that a large percentage of prescriptions performed for allergy treatment in daily clinical practice are off label. The clinicians struggle on a daily basis with the responsibility to balance risk-benefits of an off-label prescription while involving the patients and their families in this decision. It is crucial to increase awareness of this reality not only for the clinician, but also to the global organizations and competent authorities. New measures for surveillance of off-label use should be established, namely through population databases implementation. There is a need for new proposal to correct the inconsistency between the priorities for pediatric drug research, frequently dependent on commercial motivations, in order to comply to the true needs of the children, especially on the respiratory and allergy fields.

Keywords: Child, Preschool child, Off-label use, Unlicensed, Asthma, Urticaria, Atopic dermatitis, Rhinitis, Anti-asthmatic agents, Drugs

Introduction

The majority of drugs prescribed have not been tested in children and safety and efficacy of children’s medicines are frequently supported by low quality of evidence [1]. In Europe the percentage of authorized medicines for children is 33.3% [2]. This is explained by the lack of clinical research in this population, caused by ethical, scientific and technical issues, but also commercial priorities [3,4]. Therefore, most of the therapies prescribed to children are on an off-label or unlicensed basis [1].

Global legislation and regulatory efforts have been done to overpass these limitations aiming to produce proper research in the pediatric population, promoted by an International Conference on Harmonization (ICH) guidelines for clinical investigation of medicinal products in the pediatric population [5]. Since 1997, the Food and Drug Administration (FDA) in the United States of America (US) produced several regulation/legislation initiatives (Pediatric Rule Regulation, 1998; Best Pharmaceutical for Children Act, 2002 and Pediatric Research Equity Act, 2003) [6,7]. In Europe (EU), followed by US experiences, new regulations were implemented since January 2007 [8]. In both continents the measures taken encased financial incentives to the industry, the addition of 6 months extra patent protection and an additional 2 years market exclusivity for orphan medicines [1,3]. Furthermore, World Health Organization (WHO) adopted in 2007 the WHA60.20 Resolution “Better Medicines for Children” to undertake activities in the interest of improving pediatric medicines research, regulation and rational [4]. One of the most important was the establishment of
the Model List of Essential Medicines for Children, now in its 4th version [9]. However, major discrepancies between drug prescription patterns in children and the drugs granted pediatric exclusivity still exists. Looking back to the last 5 years of the Pediatric Regulation from the European Medical Agency (EMA) [Regulation(EC) N°1901/2006], 600 pediatric investigation plans (PIP) were performed, of those 453 referred to not yet authorized drugs, while the remaining related to new indications. However, no specific therapeutic area was addressed more than the other, and as far as pneumology and allergology are considered, they only accounted for 4% of PIP [10]. At the same time, 30% of the prescribed drugs for children are for the respiratory system. This suggests that pediatric studies still do not address the real need in pediatric drug development despite an overall increase of medicines now available for children. Most of the drugs available on the market, specially those considered for the treatment of allergic diseases, are still not specifically tested in children, particularly in the younger ones. The aim of this review is to describe and discuss the current off-label use of medicines in the treatment and control of allergic diseases in children.

Review
Definitions and concepts
For approval of a new medicine, the manufacturer is required to provide the relevant national medicines regulatory authority specific information about its quality, safety and efficacy. When successful, the new medicine/formulation is approved and a Marketing Authorization is issued along with the Summaries of Product Characteristics (SPC) [11]. However, the use of drugs outside their authorized SPC is not the concern of the authorities and is the sole responsibility of the prescriber [12].

Off-label use (unlabelled or unapproved) refers to prescription and/or administration of a drug outside the terms of the marketing authorization, in a way not detailed in the SPC. An unlicensed (unregistered) use is described as a formulation or dosage that has not been approved in the country in which it is prescribed or administered [11,13,14]. However, in the literature, the exact definition varied between authors through time. In a recent systematic review, different off-label types of use were found, some considered dose, frequency and route of administration, while others only contra-indications or age range [11]. In an effort to produce a common definition for future research and regulatory purposes, Neubert et al. through a systematic review of the literature and a Delphi survey with 34 experts from different areas, provided common definitions for off-label drug use in children [14]. "Pediatric off-label use" included all pediatric uses of a marketed drug not detailed in the SPC, namely: therapeutic indication; therapeutic indication for use in subsets (like age groups); appropriate strength (dosage by age); pharmaceutical form and route of administration [14]. For the purposes of this review this off-label definition was considered.

Trends of off-label prescription in children
To ascertain the trends of off-label use in children, especially in respiratory and allergic diseases, a systematic search of the literature was performed in Pubmed-Medline in July 2013 using the terms associations, "(off-label OR unlicensed OR unapproved OR unregistered)" AND "children". The studies approaching the general prevalence of off-label use that reported allergic and/or respiratory diseases data are described in Table 1. The percentage of off-label use varied widely between studies, ranging from 3 to 51% of prescriptions, and reaching a prevalence of 78%, when considering patients that received at least one off-label medicine. This variability can be explained by the different settings (countries), age range and population sample (outpatient, inpatient, population databases from pharmacies or from medical prescription records). Sturkenboom et al., compared three different countries prescription patterns (Italy, United Kingdom and Netherlands) that, despite being quite similar, off-label prescriptions percentages differed, which could be explained by different pediatric authorization status of the drugs in these countries [15]. A systematic review assessing off-label prescription in children found it to be common in all settings, but higher rates were seen for neonatal versus pediatric wards and for hospital versus community settings [16]. Therefore, off-label prescription should be assessed carefully and adapted to each reality and population.

Frequency of drug prescription increases with age; however the number of off-label medicines use decreases. The highest proportion of off-label prescription in children occurs in the first two years of life [18,20,22,24-26,29,31,34-36]. In an outpatient setting in the US, the adjusted probability of receiving at least one off-label prescription in a medical visit was 59% in children's aged 6 to 12 years, increasing to 65% from 2 to 6 year of age, to 67% if they had 1 to 2 years of age and 74% if less than 1 year (p < 0.001) [26]. Furthermore, probability could increase by 26 to 39% if they received more than one drug (p < 0.001) [26]. Nevertheless, this is not consistent in all studies. In a recent outpatient population based sample analysis in Germany there was a predominance of off-label medication use from 3 to 13 years of age [17]. The main reason for this difference can be related with the study population, mainly composed by healthy children. When considering children that resort to health care versus those that are hospitalized results differ. In a study addressing children admitted to different pediatric wards the odds of being
| Reference         | Country         | Setting                                      | Study design*                                                                 | Age        | No patients | No Prescriptions | Off-label type       | Off-label% Total | Resp. |
|-------------------|-----------------|----------------------------------------------|------------------------------------------------------------------------------|------------|-------------|------------------|---------------------|------------------|-------|
| Knopf, 2013 [17]  | Germany         | Population based sample (KiGGS)              | Prospective; drug-use assessed by survey                                     | 0 to 17 years | 8899        | 12667            | Age, dose, indication | 30                | 37    |
| Morais-Almeida, 2013 [12] | Portugal     | Allergy outpatient clinic                    | Retrospective; clinical files analysis in 2012                               | 0 to 6 years | 500         | 1224             | Age, dose, indication | 35                | 77    |
| Ribeiro, 2013 [18] | Portugal        | ED; University Hospital                      | Retrospective; random sample of children attending to the ER for 9 months in 2010 | 0 to 17 years | 700         | 724              | Age, dose, indication, route | 32                | 28    |
| Ballard, 2012 [19] | Australia       | Pediatric general ward, acute-care university Hospital | Retrospective; two groups of 150 consecutive pediatric patients admitted in July 2009 and Jan. 2010 | 1 day to 11 years | 300         | 887              | Age, dose, indication, route | 32                | 11    |
| Kimland, 2012 [20] | Sweden          | 34 Pediatric; 7 non-Pediatric Hospitals      | Prospective; data collection of all prescriptions, in two separate 48 hour periods (May and October 2008) | 0 to 18 years | 2947        | 11 294           | Age, dose, indication, route | 34                | 11    |
| Palcevski, 2012 [21] | Croatia        | Pediatric Ward; University Hospital          | Prospective; clinical files analysis on a pre-determined day of each month during 12 months (May 2010 to April 2011) | 0 to 19 years | 531         | 1643             | Age, indication, route | 13.3               | 5.1   |
| Olsson, 2011 [22]  | Sweden          | Population based sample (Swedish Prescribed Drug Register) | Retrospective; analysis of all outpatient prescriptions performed in 2007 | 0 to 18 years | –           | 2.19 million      | Age, dose, indication | 13.5               | 3.1   |
| Phan, 2010 [23]    | US              | ED of a tertiary-care children's Hospital    | Retrospective; all medical records admissions analysis from January to May 2007 | 0 to 18 years | 2191        | 6675             | Age, dose, indication, route | 25.6               | 31.8  |
| Morales-Carpi, 2010 [24] | Spain     | Outpatient prescriptions                    | Prospective; analysis of all prescriptions performed prior to the ED visit collected from June2005 to August 2006 (14 months) | 0 to 14 years | 336         | 667              | Indication, dose, frequency and route | 50.7               | 31.4  |
| Muhlbauer 2009 [25] | Germany         | German statutory health insurance provider  | Retrospective; analysis of all prescriptions performed during 2002          | 0 to 16 years | –           | 1.5 million       | Age, indication | 3.2               | 7     |
| Bazzano, 2009 [26] | US              | National Ambulatory Medical Care Surveys (NAMCS) | Retrospective; representative sample of outpatient visits from 2001 to 2004 | 0 to 18 years | 312 million | 484 million       | Age, indication | 62#               | 70#   |
| Jain, 2008 [27]    | India           | Tertiary care central Hospital              | Prospective study, prescription survey applied to a consecutive sample of children admitted to the ward from May to July 2006 | 1 month to 12 years | 600         | 2064             | Age, dose, frequency, indication | 51                | 53    |
| Hsien, 2008 [28]   | Germany         | Pediatric ward in tertiary care Hospital    | Prospective study of all patient files between January and June 2006         | 0 to 18 years | 417         | 1812             | Age, dose, indication | 31                | 30    |
Table 1 Summary of the studies reporting off-label medicines use and specifying respiratory off-label use (Continued)

| Study          | Country | Setting                                      | Design                               | Age, indication | Off-label percentage |
|----------------|---------|----------------------------------------------|--------------------------------------|-----------------|----------------------|
| Shah, 2007 [29]| US      | 31 tertiary care pediatric hospitals (PHIS database) | Retrospective study of all children discharged from the Hospital during 2004 | 0 to 17 years   | 355409               |
| Ufer, 2004 [30]| Sweden  | Population based sample (Statistics Sweden and the National Corporation of Swedish Pharmacists) | Retrospective study of all drug register present in the database in 2000 | 0 to 15 years   | —                    |
| Schirm, 2003 [31] | Netherland | Pharmacies dispensing records in northern Netherland (Interaction database) | Retrospective study of all drugs dispensing records in the Interaction database in 2000 | 0-16 years      | 18493 66222          |
| Pandolfini, 2002 [32] | Italy | Nine general pediatric hospitals wards | Prospective; analysis of all prescriptions performed to children in 12 week period | 1 month to 14 years | 1461 4255 |
| McIntyre, 2000 [33] | England | Suburban general practice clinic | Retrospective; study of all prescriptions performed in 1998 | 0 to 12 years   | 1175 3347             |

*All studies had a cross-sectional study design; ED- Pediatric Emergency department; off-label percentages is reported to visits or patients that received at least 1 off-label-drug; KiGGS- German Health Interview and Examination Survey for Children and Adolescents; PHIS- Pediatric Health Information System.
prescribed an off label drug almost double in children with less than 1 year of age (OR 1.80; 95% CI 1.03–3.59, adjusted to age, gender, number of medications prescribed and type of ward) [37]. At the same time, several other factors besides age interfere with the use of off label medicines. The other most commonly encountered reason for off-label prescribing was dosage, that both includes under-dosing and over-dosing [16,17,19,20,27,30,33,35,38,39]. This is expected due to the frequent dose adjustments needed to be performed in children. Other frequently reported reasons were unapproved therapeutic indication [18,22], followed by inappropriate age [17-19,24,38], frequency of drug use [18,22], and type of formulation [21]. The total absence of pediatric information in the SPC is also a common problem in off label prevalence studies. Inconsistent information between SPC was noted, namely for drugs with the same active compound but from different companies [20,40].

**Drug related problems and off-label drug use in children**

Off-label prescribing is not illegal, not necessarily wrong, and is contemplated in several pediatric guidelines, but remarkably, no reference is made that some drugs are being recommended in an unlicensed or off-label use basis [41]. Indeed, quality of drug therapies is not necessarily related to drug license status [16]. However this has several clinical, ethical and safety issues and there is no explicit guide to help clinicians assess the appropriateness of off-label prescribing [21]. Often it is necessary to use medicine in an off-label basis, but this should be appraised according to clinical indications, therapeutic alternatives and risk-benefit analysis, and it is required to obtain informed consent from the patient or guardian [12]. Repeatedly a question is posed in the literature [11] and clinicians minds: “Is off-label use more likely to be implicated in an Adverse Drug Reaction?”

A recent review that accessed the relationship between off-label and unlicensed medicine use and adverse drug reactions (ADR) in children concluded that good quality of evidence is lacking to answer this question; different methodologies are used and definitions of off-label and unlicensed are not consensual between studies [11]. However, results of previous studies have indicated that there might be an association between off-label use and ADR risk [11]. In all ADRs reported over a decade in Danish children, one-fifth was associated with off-label prescriptions [42].

Evidence has been contradictory and varies widely. In studies with prospective design, incidence of ADR in off-label drugs ranged from 2 to 39% [11]. Santos et al. reported that in an inpatient population, off-label drug use was significantly associated with ADRs (relative risk 2.44; 95% CI 2.12, 2.89) [39]. In another inpatient sample, Neubert et al. reported a higher prevalence of ADR with off-label use compared with licensed ones (6.1 versus 5.6%). On the other hand, evaluating an outpatient setting showed a frequency of ADR 2-fold higher among licensed medication than in off-label, though the overall frequency of ADR was low (<1%) [23].

Respiratory diseases treatments have been reported in several associations with adverse reactions and off-label prescription. In a retrospective analysis of all ADR reported from the Swedish Drug Information System in 2000, medications used for asthma treatment were the most frequently associated with adverse reactions. Of those, 31% were being used off-label [30]. In another study regarding a pharmacovigilance prospective survey in France, exposure to drugs of “Respiratory System” in a multivariate analysis was associated with a decreased risk on ADR (0.20; 95% CI 0.07, 0.60). This study also related the off-label use of a drug due to a different indication with an increased risk of ADR, particularly in infants (3.94; 95% CI 1.12, 13.84) [43]. Several factors interfere in this unknown relationship of off-label medicines and ADR, as age, type of drug, disease and previous evidence of that medication use. Any decision about off-label prescription should weight risks and benefits and has to be based on value judgments that must involve parents or guardians in the decision [44].

**Off-label prescription for asthma treatment in children**

Considering the global trends of outpatient prescription in children, allergy and asthma medicines are on the top of the most dispensed drugs [45]. If only respiratory medication is considered, asthma therapies are the most frequently prescribed (40.7% of all prescriptions) [46]. Therefore, knowledge of the authorized drugs for asthma is essential for adequate patient care. The most commonly used drugs for treating asthma are presented in Table 2, accordingly to the authorized age and maximum allowed dose limits.

Asthma management guideline recommendations, namely Global Initiative for Asthma (GINA) or Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma (EPR-3) [49,50] are widely followed by physicians, and both provide recommendations for all age groups; however, evidence supporting recommendations for preschool children is limited. The mainstay treatment for asthma are inhaled corticosteroids (ICS), but guidelines often do not provide specific recommendations for upper doses limits specially in children [50]. In this age group, namely in preschool children, inhaled corticosteroids are also the most recommended for long-term asthma treatment, mainly based in the previous experience in adults and in older children, though they advise that dose-responses are not well studied [49-51] and indeed “children are not a small size adult”. Asthma treatment poses
Table 2 Drugs used for treatment of asthma in children and authorizations for their use according to age, dose and indication

| Category                              | Drug                | Indication                        | Age lower limit | Maximum allowed dose |
|---------------------------------------|---------------------|-----------------------------------|-----------------|----------------------|
|                                       |                     |                                   | Europe*         | USA*                 |
| Inhaled corticosteroids               | Budesonide (DPI; MDI) | Asthma prophylactic treatment     | 2 years         | 400 μg/day – 2 to 6 years |
|                                       |                     |                                   |                 | 800 μg/day – 6 to 18 years |
|                                       | Budesonide (INH)    |                                   | 6 months        | 2000 μg/day          |
|                                       |                     |                                   |                 | 500 μg/day           |
|                                       | Fluticasone (DPI; MDI) |                               | 12 months       | 200 μg/day – 1 to 4 years; |
|                                       |                     |                                   |                 | 200 μg/day (DPI) or  |
|                                       |                     |                                   |                 | 176 μg/day (MDI) – 4 to 11 years; |
|                                       |                     |                                   | 4 years         | 400 μg/day – 4 to 16 years; |
|                                       |                     |                                   |                 | 2000 μg/day (DPI) or  |
|                                       |                     |                                   |                 | 1760 μg/day (MDI) ≥ 12 years; |
|                                       | Mometasone furoate (DPI) |                               | 12 years        | 800 μg/day          |
|                                       |                     |                                   |                 | 110 μg/day – 4 to 11 years; |
|                                       | Beclomethasone Dipropionate |                        | 4 years         | 400 μg/day – 4 to 12 years; |
|                                       |                     |                                   |                 | 160 μg/day – 5 to 11 years; |
| |                                      |                     |                                   | 5 years         | 2000 μg/day ≥ 12 years; |
| |                                      |                     |                                   |                 | 640 μg/day ≥ 12 years; |
| Oral anti-leukotrienes                | Montelukast         |                                   | 6 months        | 4 mg/day – 6 months to |
|                                       |                     |                                   |                 | 5 mg/day – 6 to 14 years; |
|                                       |                     |                                   |                 | 10 mg/day ≥ 15 years; |
| Short-acting β2 agonists              | Salbutamol or Albuterol | Asthma reliever treatment          | None            | 800 μg/day <12 years (MDI) |
|                                       |                     |                                   |                 | 1080 μg/day (MDI)    |
|                                       | Terbutaline (DPI)   |                                   | 3 years         | 4 mg/day – 3 to 12 years; |
|                                       |                     |                                   |                 | 6 mg/day ≥ 12 years; |
| Long-acting β2 agonists               | Salmeterol (DPI)    | Asthma prophylactic treatment     | 4 years         | 100 μg/day           |
|                                       | Formoterol (DPI)    |                                   | 6 years         | 24 μg/day – 5 to 12 years; |
| |                                      |                     |                                   |                 | 24 μg/day            |
| |                                      | Budesonide/ Formoterol (DPI) |                   | 6 years         | 320/18 μg/day – 6 to 12 years; |
| |                                      |                     |                                   |                 | 640/18 μg/day        |
| |                                      |                     |                                   |                 | 640/18 μg/day ≥ 12 years; |
| Combination long-acting β2 agonists with inhaled corticosteroids | Fluticasone/Salmeterol |                               | 4 years         | 200/100 μg/day (DPI, MDI) – 4 to 11 years; |
| |                                      |                     |                                   |                 | 200/100 μg/day (DPI, MDI) – 12 years; |
| |                                      |                     |                                   | 12 years        | 1000 μg/100day (DPI, MDI) – ≥ 12 years; |
| |                                      |                     |                                   |                 | 1000 μg/100day (DPI, MDI) – ≥ 12 years; |
| |                                      |                     |                                   |                 | 460/42 μg/day (MDI)  |

DPI- dry powder inhaler; MDI- Metered dose inhaler; INH- inhalation suspension *Data obtained in the Summaries of Product Characteristics (SPC) of one European country (Portugal, Infarmed [47]), except for mometasone furoate obtained from the UK SPC *Data obtained in the FDA approved Drugs Database [48]. Comparison between an European country (regulated by EMA and the national authority) and the United States of America (regulated by FDA).
several challenges in very young children; often an overlap between recurrent wheezing and asthma phenotypes occurs, making diagnosis and therapeutic decisions controversial [52,53]. Moreover, some therapeutic options are not deprived of side effects [49,52].

In children, inhaler type and child's ability to use it correctly also interferes with the treatment. Beclomethasone, budesonide and fluticasone are available as either metered dose inhaler (MDI) or dry powder inhaler (DPI). Preschool children are not able to cooperate with the proper inhalation technique demanded by DPI, therefore these devices are not licensed for this population [52]. Furthermore, some new drugs like mometasone and ciclesonide are still not approved under 12 years [52].

In long-term treatment, if control is not achieved, other treatment associations can be considered, but their efficacy and safety are also not established in some cases. Long acting β2 agonists (LABA) are endorsed in the EPR-3 as one option for step-up therapy for persistent asthma in association to inhaled corticosteroids. Though they advise that these drugs aren't adequately studied in children with less than 4 years of age, they are recommended as an add-on in the upper steps of the stepwise approach [50]. On the other hand, GINA guidelines specifies asthma therapy for children under 5 years of age, where LABA aren’t approved, indicating oral anti-leukotriene's as an option [54,55]. Guidelines are recommendations on the appropriate management, diagnosis and treatment, but they differ between each other and vary widely between countries, however they do not replace clinician's knowledge and skills. Several studies assessed the pediatric use of asthma drugs in different countries through cohort and cross-sectional studies [46,56,57]. TEDDY study is a 6 years retrospective analysis of outpatient medical records concerning pediatric asthma that combined databases from Netherland, Italy and United Kingdom and described the use of asthma drugs to be more frequent in children less than two years of age [56] to whom drug authorizations are scarce (Table 2). As expected, asthma treatment in children under 2 years present the highest prevalence of off-label use [12,46,56,57]. The most frequent drugs used off label are the short acting β2 agonist (SABA) salbutamol, ranging from 24 to 45% [56,57], and inhaled corticosteroids, from 26 to 80% [12,56,57]. Fixed combination of ICS and LABA were also often prescribed [56]. When considering types of off-label use, salbutamol and ICS were the most frequently reported due to age limits (19%), and salmeterol-fluticasone association due to inadequate indication [33,57]. Other studies report off-label use of these drugs due to higher than recommended doses; this could be explained mainly owing to inconsistencies found between the SPC and country guideline recommendations [19,35]. Many children with asthma are not managed in accordance with the set guidelines, as they vary widely in the literature and are not consistent with the SPC, leaving physicians to prescribe off-label. Most recognize it and believe that off-label prescription is appropriate, however they have efficacy and safety concerns. Moreover in a recent study only one third of the physicians self-reported that children's guardians/parents were informed of off-label treatment use [58].

Off-label use for rhinitis treatment in children
Allergic rhinitis is the most prevalent chronic allergic disease in children [59]. Oral second-generation anti-histamines and intranasal corticosteroids are considered the first line treatments [59-61]. In Table 3 are described some examples of the most often used drugs for allergic rhinitis, accordingly to the age limit and maximum allowed dose. The majority of intranasal corticosteroids and some of the anti-histamines lack pediatric approval and this is recognized by the guidelines [59,61]. These drugs are recommended for children by extrapolation from pharmacological and clinical data in adults. However, the absorption, distribution and metabolism in children diverge from adults and age-related differences in children exist in their ability to metabolize, absorb, excrete and transform medications, therefore efficacy and safety might be affected [59,62]. Although nasal corticosteroids can be associated with some side effects, including bone mineral density loss, adrenal suppression and growth retardation, these were only reported in one study using beclomethasone [60,62]. Therefore, the lowest possible dose for symptoms control is favored [61]. Intranasal corticosteroid use before age of 2 is considered off-label and only mometasone is authorized in less than 4 years of age in the US (Table 3). As for anti-histamines, accordingly to the most recent guideline update, first generation drugs should not be used for rhinitis in children due to their side effects [63]. However, the most frequently available anti-histamines over the counter in the US are from first generation. This raised public health concerns about their use in children and, in the US, campaigns have been conducted to advise for safety concerns and recommend against their use under the age of two [64]. If considering an outpatient setting, the majority of off-label prescriptions were from pediatricians (54.4%), but a large number, 34.3%, were self-medications [24]. Despite their widely use only few studies have been performed to assess the magnitude of off-label drug in children for rhinitis.

In a recently published study assessing off-label use in an allergy outpatient clinic, the most frequently prescribed drugs were nasal corticosteroid in 76% of all prescriptions, anti-histamines were used off-label in 22% [12]. T’ Jong et al. study reported that of all respiratory
drug prescriptions assessed to be used in a pediatric population, half of the patients were prescribed antihistamines and nasal corticosteroids in an off-label basis [46]. In other studies assessing systemic anti-histamines, off-label prescribing ranged from 6.5% to 43% [17,23,30,33,35]. Cetirizine [65,66], levocetirizine [62,67] and loratadine [68] have been the most investigated for long term safety in pediatric population. Despite pharmacokinetic studies have been performed in new generation anti-histamines, long-term safety studies in children are still lacking [69,70]. Indeed, due to the proven efficacy of nasal corticosteroids and anti-histamines on disease control in children by reducing disease-associated impairment and improving disease-related quality of life, more studies are needed about safety in order for physicians to perform a rational decision of the large number of options available in the market [62,69,71].

Off-label medicines use for treating urticaria and atopic eczema in children

In a joint initiative, the European Academy of Allergology and Clinical Immunology (EAACI), the EU-funded
network of excellence, the Global Allergy and Asthma European Network (GA2LEN), the European Dermatology Forum (EDF) and the World Allergy Organization (WAO) published a guideline for urticaria management [72]. In it was recommended as the first line treatment for urticaria the use of oral anti-histamines in an up-dosing step up therapy until up to 4 times the dose. These new recommendations were also advised for children, adjusting the dose accordingly to the weight [72]. Recent randomized, double-blind, placebo controlled trials in adults support the efficacy and safety of this up-dosing use, namely in cold contact urticaria [73,74]. Nevertheless, due to the absence of controlled trials in children, these changes were not updated in the SPC of the anti-histamines in the market and as stated above only a few of them were actually studied for their long term effects in children. This explains why a large portion of the off-label type of use when considering anti-histamines is due to a different dose prescription [12]. For chronic disease it is also important not only efficacy and safety, but also compliance to the treatment. Children pediatric formulations, namely under 6 years of age, are usually liquid and it is necessary to make them stable, sterile, pleasant and long lasting. Furthermore as children grow, drug doses should be adapted to weight and, to avoid dosing errors, the means to deliver accurate doses of these liquid formulations need to be available [62]. In atopic dermatitis, anti-histamines also are considered as potential benefit to reduce pruritus, and although no evidence exists to support their role in treatment they can be useful in reducing this disturbing symptom in children [69].

Accordingly to the most recently published guidelines for atopic dermatitis the main treatment is skin hydration, topical anti-inflammatory medications and antipruritic therapy [75-77]. For anti-inflammatory medication, topical glucocorticosteroids or topical calcineurin inhibitors are used. For topical corticosteroids numerous substances are available, grouped by potency. Potent and very potent corticosteroids (Group III and IV) are more likely to cause systemic or local side effects (like adrenal suppression, skin atrophy or striae) than group I (mild) and II (moderate strength); therefore the first should be avoided for treatment in infants, whose higher surface area to body weight ratio and age dependent maturation of the skin barrier function leaves them vulnerable to over-dosing [75,78]. According to the FDA, use of these products are also limited by age and duration of treatment [78]. Still and specially from birth to 4 years of age, topical corticosteroids were prescribed off-label in 13% of all prescriptions, of those 58% due to high dosage use [35]. Recent guidelines recommend that for mild disease activity, a small amount of topical corticosteroids twice to thrice weekly until reaching a mean monthly dose of 15 grams (g) in infants, 30 g in children and up to 60 to 90 g in adolescents and adults [75].

Nowadays new topical anti-inflammatory alternatives include calcineurin inhibitors and fourth generation corticosteroids. This fourth generation corticosteroids, like methylprednisolone aceponate seem to have a favorable benefit-risk-ratio in this age group [79]. Regarding topical immunomodulators, calcineurin inhibitors, like tacrolimus and pimecrolimus, as they don’t cause skin atrophy, are favored for long-term management and to be used in delicate body areas, such as the eyelid region, the perioral skin, genital area, the axilla or the inguinal fold [80]. As a result of the immunosuppressant activity of these drugs there are concerns about their potential to promote skin infections and malignancies, particularly lymphomas, following long-term treatment [80]. These drugs are only approved for children with more than 2 years of age by FDA and EMA (Table 3). Due to the high prevalence of atopic dermatitis in children, which begins in over 60% of cases during the first year of life, usually affects more sensitive-skin areas and have a higher body surface/volume ratio that enhances the risk of systemic exposure to corticosteroids, it was seen an increase of use in topical calcineurin inhibitors [77,80]. Off-label use, particularly in infants in the US, reached a high prevalence of prescriptions in 2004, approximately 525,000 (14% of yearly prescriptions) for pimecrolimus and 69,000 (7%) for tacrolimus [80]. This led FDA to include a black box warning in 2005, changed to a box warning in 2006, on the labels of topical tacrolimus and pimecrolimus. Still, further discussion has occurred and even with large epidemiological data, at current time, FDA maintains that may be “a possibility of an association” [80]. However, guidelines recommend clinicians to use tacrolimus ointment, specially for eczema on the face, eyelid, and skin folds that is unresponsive to low-potency topical steroids in children older than 2 years [75,77]. Other systemic drugs for atopic dermatitis treatment also recommended off-label in children and adolescents is cyclosporine, however only reserved in the most severe and refractory to classical treatment and usually demanding specialized care [76].

Unmet needs

According to the World Health Organization the ideal medicine for a children is “one that suits the age, physiological condition and body weight of the child taking them and is available in a flexible solid oral dosage form that can be taken whole, dissolved in a variety of liquids, or sprinkled on foods, making it easier for children to take” [81]. However this reality is far from us and still, as it was seen, drugs are not adequately studied for children.

In order to improve drug use and safety of treatment in children there is a need to increase research not only
for new drugs, but also in medicines that are in market but are not adequately adjusted for children. Several worldwide regulatory efforts, namely those included in the initiative “Better Medicines for Children” allowed that a large number of new products with pediatric indications and age-appropriate pharmaceutical forms to be now authorized and made available. Furthermore, a high number of agreed pediatric investigation plans indicate that further products are appearing. However, there is an imbalance between the priorities for pediatric drug research and the need of the children. This is specially visible for respiratory and allergy treatment medicines [3,10].

Furthermore, physicians frequently encounter an inconsistency in what is proposed on the guidelines and the drugs summary of product recommendations [35]. There is an urgent need for regulations of off-label prescribing not only for medical institutions, but also for physicians [82]. In a daily basis they are confronted with questions of safety, apprehension of potential ADR, efficacy and ethical issues. As Gazarian et al. reported most physicians believe that off-label prescribing is adequate and they are doing it considering that the benefits outweigh the risks, but due to lack of evidence, frequently they are unaware of the true balance [13].

The overall level of unlicensed and off-label pediatric prescribing suggests the need to perform well designed clinical studies in children, for that pharmaceutical industry and academic organizations should be encouraged [37,82]. The previously implemented Pediatric Use Marketing Authorization (PUMA), which offered 8 years of data protection and 10 years of market exclusivity to any new off-patent product developed exclusively for use in the pediatric population was not successful and in the last 5 years only one was granted. Probably it did not overweight the economical risks and competition with previously implemented drugs. New measures are needed to encourage the market in a new path. Furthermore, more awareness should be enforced using population-based databases to monitor off-label prescription and by that increase awareness of the true children’s needs and interests.

Conclusions

Off-label use in children is common and differs between countries, inpatient and outpatient settings and age. Respiratory and allergy medicines are on the top of the most prescribed off-label drugs in children, nevertheless this has not been accompanied with new research of their safety and efficacy in children, specially with those drugs already in market. In this narrative review it was recognized that a large percentage of drugs prescription in an allergist daily clinical practice are off-label. It is fundamental to increase awareness of this reality, as it is the responsibility of the clinician to balance risk-benefits of the prescription. Parents/guardians should be informed and involved in the decision in order to prevent misunderstandings, increase compliance and awareness to adverse effects in the pursuance of a good clinical outcome. There is a need for new studies with a better design to access long-term safety and efficacy of respiratory and allergy on-market drugs in children, primarily in those under two years of age. New ways should be found by the competent authorities to promote more research accordingly to the patients needs, namely on respiratory and allergy field.

Abbreviations

ADR: Adverse drug reactions; EPR-3: Expert panel report 3: Guidelines for the diagnosis and management of asthma; EAACI: European Academy of Allergology and Clinical Immunology; EDF: European Dermatology Forum; EU: Europe; EMA: European Medicines Agency; DPI: Dry Powder Inhaler; FDA: Food and drug administration; GA2LEN: Global Allergy and Asthma European Network; GINA: Global Initiative for Asthma; ICH: International conference on harmonization; ICS: Inhaled corticosteroids; LABA: Long acting β2 agonist; MPA: Metered dose inhaler; PIP: Pediatric investigation plans; PUMA: Pediatric Use Marketing Authorization; SABA: Short acting β2 agonist; SPC: Summaries of product characteristics; TEDDY: Task-force in Europe for Drug Development for the Young; US: United States of America; WAO: World Allergy Organization.

Competing interests

The authors declare that they have no competing interests.

Authors’ contributions

DS, IA and MMA equally contributed to writing the manuscript. All authors have reviewed and approved the final version of manuscript.

Author details

1. Immunoallergology Department, Centro Hospitalar de São João, Alameda Prof. Hernâni Monteiro, 4200-309 Porto, Portugal. 2. Immunoallergology Department, CUF Descobertas Hospital, R. Mário Botas, 988-018 Lisboa, Portugal. 3. Department of Allergy and Immunology, Hospital Quirón Bizkaia, Carretera de Leioa-Unbe, 33 Bis, 48950 Erandio, Spain. 4. Center for Research in Health Technologies and Information Systems, University of Porto, Porto, Portugal.

Received: 3 September 2013 Accepted: 22 January 2014
Published: 14 February 2014

References

1. Dunne J. The European Regulation on medicines for paediatric use. Paediatr Respir Rev 2007, 8:177–183.
2. Ceci A, Felix M, Baiardi P, Bonifazi F, Catapano M, Giaquinto C, Nicolosi A, Strunkboom M, Neubert A, Wong I. Medicines for children licensed by the European Medicines Agency (EMA) the balance after 10 years. Eur J Clin Pharmacol 2006, 62:947–952.
3. Boots I, Sukhai RN, Klein RH, Hall RA, Wit JM, Cohen AF, Burggraaf J. Stimulation programs for pediatric drug research–do children really benefit? Eur J Pediatr 2007, 166:899–955.
4. Hoppu K, Arabavasi G, Garcia-Bournissen F, Gazarian M, Kears GL, Nakamura H, Peterson RG, Sri Ranganathan S, de Wilde SN. The status of paediatric medicines initiatives around the world–What has happened and what has not? Eur J Clin Pharmacol 2012, 68:1–10.
5. Clinical Investigation of Medicinal products in the pediatric population. http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/ Efficacy/E11/Step4/E11_Guideline.pdf.
6. Pediatric Research Equity Act of 2003. http://www.fda.gov/downloads/Drugs/ DevelopmentApprovalProcess/DevelopmentResources/UCM077853.pdf.
7. Best Pharmaceuticals for Children Act. http://www.fda.gov/RegulatoryInformation/Legislation/FederalFoodDrugandCosmeticAct/DFCAAct/SignificantAmendments totheFDCAAct/ucm148011.htm.
8. Regulation (EC) number 1901/2006 of the European parliament and of the council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EC) No 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004.http://ec.europa.eu/health/files/medicines/rule_2002/06_2006_reg_2010_en.pdf.

9. 4th WHO Model List of Essential Medicines for Children (April 2013). http://www.who.int/medicines/publications/essentialmedicines/en/index.html.

10. Report from the commission to the European Parliament and the Council, Better Medicines for Children — From Concept to Reality; General Report on experience acquired as a result of the application of Regulation (EC) No 1901/2006 on medicinal products for paediatric use. http://ec.europa.eu/health/files/medicines/2013_com443/medicines_report-com(2013)443_en.pdf.

11. Mason J, Pirimohamed M, Nunn T: Off-label and unlicensed medicine use and adverse drug reactions in children: a narrative review of the literature. Eur J Clin Pharmacol 2012, 68:21–28.

12. Morais-Almeida M, Cabral AI: Off-label prescribing for allergic diseases in pre-school children. Allergol Immunopathol (Madrid) 2013, http://dx.doi.org/10.1016/j.alli.2012.02.011.

13. Gazarian M, Kelly M, McPhee JR, Gaudrins LV, Ward RL, Campbell TJ: Off-label use of medicines: consensus recommendations for evaluating appropriateness. Med J Aust 2006, 185:544–548.

14. Neubert A, Wong IC, Bonifazi A, Catapano M, Felisi M, Baiardi P, Giaquinto C, Knibbe CA, Sturkenboom MC, Ghaeb MA, Ceci A: Defining off-label and unlicensed use of medicines for children: results of a Delphi survey. Pharmaco 2008, 58:316–322.

15. Sturkenboom MC, Verhamme KM, Nicolosi A, Murray ML, Neubert A, Caduri D, Picelli G, Sen EF, Giaquinto C, Cantarutti L et al: Drug use in children: cohort study in three European countries. BMJ 2008, 337:a2245.

16. Pandolfi C, Bonati M: A literature review on off-label drug use in children. Eur J Pediatr 2005, 164:552–558.

17. Kroop H, Wolf IJ, Sangaran G, Zhuang W, Rascher W, Neubert A: Off-label medicine use in children and adolescents: results of a population-based study in Germany. BMC Public Health 2013, 13:631.

18. Ribeiro M, Jorge A, Macedo AF: Off-label drug prescribing in a Portuguese paediatric emergency unit. Int J Clin Pharm 2013, 35:30–36.

19. Ballard CD, Peterson GM, Thompson AJ, Beggs SA: Off-label use of medicines in paediatric inpatients at an Australian teaching hospital. J Paediatr Child Health 2013, 49:38–42.

20. Kimland E, Nydert P, Odlind V, Bottiger Y, Lindemalm S: Pediatric prescribing practice with focus on off-label prescriptions at Swedish hospitals - a nationwide study. Acta Paediatr 2012, 101:772–778.

21. Palcevski G, Skocibusic N, Vlahovic-Palcevski V: Off-label and unlicensed drug use in children outside the hospital. Pediatrics 2003, 111:291–295.

22. Pandolfi C, Impicciatore P, Provasi D, Rocci F, Campi R, Bonati M: Off-label use of drugs in Italy: a prospective, observational and multicentre study. Acta Paediatr 2002, 91:339–347.

23. McIntyre J, Conroy S, Avey A, Cons.M, Choonara I: Unlicensed and off-label prescribing of drugs in general practice. Arch Dis Child 2000, 83:498–501.

24. Bucheler R, Schwab M, Morike K, Kalchthaler B, Mohr H, Schroder H, Schwoerer P, Gleiter CH: Off label prescribing to children in primary care in Germany: retrospective cohort study. BMJ 2002, 324:1311–1312.

25. Elkins-Daukes S, Helm’s PJ, Simpson CR, Taylor MW, McKay JS: Off-label prescribing to children in primary care: retrospective observational study. Eur J Clin Pharmacol 2004, 60:349–353.

26. Lindell-Osawagui L, Korhonen MJ, Saano S, Helin-Tanninen M, Naaranlahti T, Kokki H: Off-label and unlicensed drug prescribing in three paediatric wards in Finland and review of the international literature. J Clin Pharmacol 2009, 49:277–287.

27. Kndour MR, Hallak HO, Alyasa KS, AlShahed QN, Hawwa AF, McElnay JC: Extent and nature of unlicensed and off-label medicine use in hospitalised children in Palestine. Int J Clin Pharm 2011, 33:650–655.

28. Neubert A, Dormann H, Weiss J, Egger T, Criegee-Reck M, Rascher W, Brune K, Hinz B: The impact of unlicensed and off-label drug use on adverse drug reactions in paediatric patients. Drug Saf 2004, 27:1059–1067.

29. Dos Santos L, Heinke I: Drug utilization study in pediatric prescriptions of a university hospital in southern Brazil: off-label, unlicensed and high-alert medications. Farm Hosp 2012, 36:180–186.

30. Lass J, Iris A, Pisarev H, Leinekummer T, Lustra I: Off-label use of prescription medicines in children in outpatient setting in Estonia is common. Pharmacoepidemiol Drug Saf 2011, 20:474–481.

31. Boerdan FA: Use of unlabelled and off licence drugs in children. Use of unlicensed drugs may be recommended in guidelines. BMJ 2000, 320:1210.

32. Aagaard L, Hansen EH: Prescribing of medicines in the Danish paediatric population outside the licensed age group: characteristics of adverse drug reactions. Br J Clin Pharmacol 2011, 71:51–75.

33. Horen B, Montastruc JL, Lapeyre-Mestre M: Adverse drug reactions and off-label and off-label use drug in paediatric patients. Br J Clin Pharmacol 2002, 54:665–670.

34. Lenk C, Koch P, Zappel H, Wiesemann C: Off-label, off-limits? Parental awareness and attitudes towards off-label use in paediatrics. Eur J Pediatr 2009, 168:1473–1478.

35. Chai G, Gouveia-Le, McMahon AW, Trinidad JP, Staffa J, Murphy D: Trends of prescriptions in Sweden of unlicensed drug utilization in US children, 2002–2010. Pediatrics 2012, 130:23–31.

36. J'ong GW, Eland JA, Sturkenboom MC, van den Anker JN, Stricker BH: Unlicensed and off-label prescription of respiratory drugs to children. Eur Respir J 2004, 23:810–813.

37. Autoridade Nacional do Medicamento e Produtos de Saúde: http://www.anamed. pt/infomed/pesquisaspah.

38. FDA Approved Drug Products. http://www.accessdata.fda.gov/scripts/cder/ drugatfda/index.cfm.

39. Global Strategy for Asthma Management and Prevention. [http://www. ginaasthma.org].

40. National Asthma Education and Prevention Program, Third Expert Panel on the Diagnosis and Management of Asthma. Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma. http://www.ncbi.nlm.nih.gov/books/NBK7232/.

41. Yewale VN, Dharmapalan D: Promoting appropriate use of drugs in children. Int J Pediatr 2012, 2009:5670.

42. Smyth AR, Barbato A, Beydon N, Bisgaard H, de Boeck K, Brand P, Bush A, Fauquert B, de Jongte J, Korppi M, et al: Respiratory medicines for children: current evidence, unlicensed use and research priorities. Eur Respir J 2010, 35:267–265.

43. Grover C, Armour C, Aspenen PP, Molew R, Sani B: Medication use in children with asthma: not a child size problem. J Asthma 2011, 48:1085–1103.

44. GINA: Global Strategy for the Diagnosis and Management of Asthma in Children 5 Years and Younger. In Book Global Strategy for the Diagnosis
and Management of Asthma in Children 5 Years and Younger. Edited by Editor ed./eds. City, 2009.

55. Pedersen SE, Hurd SS, Lemanske RF Jr, Becker A, Zar JH, Sly PD, Soto-Quiroz M, Wong G, Bateman ED. Global strategy for the diagnosis and management of asthma in children 5 years and younger. Pediatr Pulmonol 2011, 46,1–17.

56. Sen E, Verhamme KM, Neubert A, Hisa Y, Murray M, Felisi M, Giaquinto C, Y-long GW, Picelli G, Baraldi E, et al. Assessment of pediatric asthma drug use in three European countries; a TEDDY study. Eur J Pediatr 2011, 170:81–92.

57. Baiardi P, Ceci A, Felisi M, Cantarutti L, Grotto S, Sturkenboom M, Baraldi E. In-label and off-label use of respiratory drugs in the Italian paediatric population. Acta Paediatr 2010, 99:544–549.

58. Mukattash T, Hawwa AF, Trew K, McElnay JC. Healthcare professional experiences and attitudes on unlabeled/off-label paediatric prescribing and paediatric clinical trials. Eur J Clin Pharmacol 2011, 67:449–461.

59. Bousquet J, Khaltaev N, Cruz AA, Denburg J, Fokkens WJ, Togias A, and paediatric clinical trials. Eur J Clin Pharmacol 2011, 67:449–461.

60. Wallace DS, Dyekwicz MS, Bernstein DI, Blessing-Moore J, Cox L, Kh K, Zuberbier T, Baena-Cagnani CE, Canonica GW, van Weel C, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy 2008, 63(Supp 86):18–160.

61. Wallace DS, Dyekwicz MS, Bernstein DI, Blessing-Moore J, Cox L, Kh K, Zuberbier T, Baena-Cagnani CE, Canonica GW, van Weel C, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy 2008, 63(Supp 86):18–160.

62. Pampura AN, Papadopoulos NG, Spicak V, Kurzawa R. Efficacy of clinical safety, efficacy, and parent and physician perceptions of levocetizine for the treatment of children with allergic disease. Int Arch Allergy Immunol 2011, 155:367–378.

63. Brozek JL, Bousquet J, Baena-Cagnani CE, Bonini S, Canonica GW, Casale TB, van Wijk RG, Ohta K, Zuberbier T, Schunemann HJ. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines: 2010 revision. J Allergy Clin Immunol 2010, 126:466–476.

64. Joint meeting on the Nonprescription Drugs Advisory Committee and the Pediatric Advisory Committee. http://www.fda.gov/ohrms/dockets/ac/07/briefing/2007–4323b1-02-FDA.pdf.

65. Simons FE: Prospective, long-term safety evaluation of the H1-receptor antagonist cetirizine in very young children with atopic dermatitis. ETAC Study Group. Early Treatment of the Atopic Child. J Allergy Clin Immunol 1999, 104:433–440.

66. Simons FE, Silas P, Portnoy JM, Catuogno J, Chapman D, Olufade AO, PharmD: Safety of cetirizine in infants 6 to 11 months of age: a randomized, double-blind, placebo-controlled study. J Allergy Clin Immunol 2003, 111:1244–1248.

67. Simons FE: Safety of levocetizine treatment in young children: An 18-month study. Pediatr Allergy Immunol 2007, 18:355–342.

68. Grimfeld A, Holgate ST, Canonica GW, Bonini S, Borres MP, Adam D, Carasco Gonzalez C, Lobaton P, Patel P, Szczeklik A, et al. Prophylactic management of children at risk for recurrent upper respiratory infections: the Preventia I Study. Clin Exp Allergy 2004, 34:1665–1672.

69. de Benedictis FM, de Benedictis D, Canonica GW: New oral H1 antihistamines in children: facts and unmeet needs. Allergy 2008, 63:1395–1404.

70. Gupta SK, Kantesaria B, Banfield C, Wang Z. Desloratadine dose selection in children aged 6 months to 2 years: comparison of population pharmacokinetics between children and adults. Br J Clin Pharmacol 2007, 64:174–184.

71. Rachelefsky G, Farar JR. A control model to evaluate pharmacotherapy for allergic rhinitis in children. JAMA Pediatr 2013, 167:380–386.

72. Zuberbier T, Axer R, Bindslsv-Jensen C, Walter Canonica G, Church MK, Gmeinm-Arnau AM, Grattan CE, Kapp A, Maurer M, Merk HF, et al. EAACI/ GA(2)LEN/EDF/WAO guideline: management of urticaria. Allergy 2009, 64:1423–1427.

73. Krause K, Kophar A, Zuberbier T, Church MK, Maurer M. Up-dosing with bilastine results in improved effectiveness in cold contact urticaria. Allergy 2013, 68:521–528.

74. Siebenhaar F, Degener F, Zuberbier T, Martus P, Maurer M. High-dose desloratadine decreases wheal volume and improves cold provocation thresholds compared with standard-dose treatment in patients with acquired cold urticaria: a randomized, placebo-controlled, crossover study. J Allergy Clin Immunol 2009, 123:672–679.

75. Ring J, Alomar A, Bieber T, Deleuran M, Fink-Wagner A, gelmetti C, Geier U, Lipcenzic J, Luger T, Orange AP, et al. Guidelines for treatment of atop eczema (atopic dermatitis) part I. J Eur Acad Dermatol Venereol 2012, 26:1045–1050.

76. Ring J, Alomar A, Bieber T, Deleuran M, Fink-Wagner A, gelmetti C, Geier U, Lipcenzic J, Luger T, Orange AP, et al. Guidelines for treatment of atop eczema (atopic dermatitis) part II. J Eur Acad Dermatol Venereol 2012, 26:1176–1193.

77. Schneider L, Tilles S, Lio P, Boguniewicz M, Beck L, LeBovidge J, Novak V, Bernstein O, Blessing-Moore J, Khan D, et al. Atopic dermatitis: a practice parameter update 2012. J Allergy Clin Immunol 2013, 131:295–299. e291–277.

78. Hengge UR, Ruzicka T, Schwartz RA, Cork MJ: Adverse effects of topical glucocorticosteroids. J Am Acad Dermatol 2006, 54:1–15. quiz 16–18.

79. Burme-Festyavi U, Wahn U. Optimizing the treatment of atopic dermatitis in children: a review of the benefit/risk ratio of methylprednisolone acetonate. J Eur Acad Dermatol Venereol 2011, 25:508–515.

80. Carr WW. Topical calcineurin inhibitors for atopic dermatitis: review and treatment recommendations. Paediatr Drugs 2013, 15:303–310.

81. Medicines: medicines for children. Fact sheet N°341. http://www.who.int/medicinesfactsheets/f341/en/.

82. Zhang L, Li Y, Liu Y, Zeng L, Hu D, Huang L, Chen M, Lv J, Yang C. Pediatric off-label drug use in China: risk factors and management strategies. J Evid Based Med 2013, 6:4–18.